Trials / Completed
CompletedNCT04972981
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors
A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 as Monotherapy in Patients With Selected Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- ADC Therapeutics S.A. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objectives of this study are to identify the recommended phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), and to characterize the safety and the tolerability of ADCT-901.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ADCT-901 | Intravenous infusion |
Timeline
- Start date
- 2021-09-09
- Primary completion
- 2024-09-13
- Completion
- 2024-09-13
- First posted
- 2021-07-22
- Last updated
- 2025-05-22
Locations
13 sites across 3 countries: United States, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04972981. Inclusion in this directory is not an endorsement.